Global Bronchial Thermoplasty Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Bronchial Thermoplasty Market Overview

The Bronchial Thermoplasty Market was valued at USD 684 Million in 2025 and is projected to reach USD 1844.28 Million by 2033, growing at a CAGR of 13.20% from 2026 to 2033. The Bronchial Thermoplasty Market is witnessing steady growth driven by the rising prevalence of severe and uncontrolled asthma, increasing adoption of minimally invasive interventional pulmonology procedures, and growing clinical preference for non-pharmacological treatment options in patients with inadequate response to standard inhaled therapies. Bronchial thermoplasty is gaining traction as a targeted airway remodeling technique that helps reduce airway smooth muscle mass and improve asthma control in patients with severe persistent asthma.

The increasing burden of respiratory diseases globally, combined with rising healthcare expenditure and improved access to advanced pulmonary care in hospitals and specialty respiratory centers, is driving adoption of bronchial thermoplasty procedures. Growing clinical evidence supporting long-term reduction in asthma exacerbations and improved quality of life is further encouraging physicians and healthcare institutions to incorporate this therapy into treatment pathways. In addition, advancements in radiofrequency-based catheter technologies and expansion of trained interventional pulmonologists are strengthening procedural adoption across developed healthcare markets, while emerging economies are gradually expanding access through specialized tertiary care centers.

Key Market Trends & Insights

• North America dominated the Bronchial Thermoplasty Market with the largest revenue share of 38.91% in 2025, supported by high prevalence of severe asthma cases, advanced healthcare infrastructure, and strong adoption of interventional pulmonology procedures across hospitals and specialty respiratory care centers.
• The Bronchial Thermoplasty Systems segment led the market with a 44.26% share in 2025, driven by increasing demand for minimally invasive asthma treatment solutions, rising clinical adoption in severe and uncontrolled asthma cases, and strong preference for device-based airway remodeling therapies in hospitals.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by rising asthma prevalence, expanding healthcare infrastructure, increasing awareness of advanced respiratory treatments, and growing adoption in China, India, and Japan.
• Catheter-Based Ablation Devices are the fastest-growing product type, projected to register a CAGR of 7.4%, reflecting increasing advancements in radiofrequency catheter technology and rising adoption of precision-based bronchial thermoplasty procedures.
• The Hospitals segment dominates the end-use category with a 52.63% revenue share in 2025, led by strong availability of advanced interventional pulmonology facilities and high patient inflow for severe asthma management.

Market Size & Forecast

• Global Market Value (2025): USD 684 Million
• Expected Market Value (2033): USD 1844.28 Million
• Forecast CAGR (2026–2033): 13.20%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Bronchial Thermoplasty Market Segmentation

Bronchial Thermoplasty Market Trends

Trend: Growth in Advanced Respiratory Interventional Procedures & Bronchial Thermoplasty Adoption

The Bronchial Thermoplasty Market is witnessing steady growth due to increasing prevalence of severe asthma and rising adoption of minimally invasive interventional pulmonology procedures. Bronchial thermoplasty is increasingly being recommended for patients with severe persistent asthma who remain uncontrolled despite high-dose inhaled corticosteroids and long-acting beta-agonists. Clinical studies, including outcomes from the AIR and AIR2 trials, have demonstrated significant reductions in severe asthma exacerbations (up to ~32–70% reduction depending on patient cohort and follow-up period), supporting wider clinical acceptance of the procedure. Hospitals and specialty pulmonology centers are expanding bronchoscopy suites and investing in radiofrequency-based bronchial thermoplasty systems such as Boston Scientific’s Alair System, which remains one of the most widely used FDA-approved platforms for airway smooth muscle reduction therapy.

Bronchial Thermoplasty Market Dynamics

Key Market Driver: Rising Burden of Severe Asthma and Expanding Interventional Pulmonology Infrastructure

The increasing global prevalence of asthma, affecting an estimated 260+ million people worldwide, is a major driver for bronchial thermoplasty adoption, particularly among patients with severe, treatment-resistant asthma. Hospitals and specialty clinics are increasingly incorporating bronchial thermoplasty into advanced asthma management pathways as an adjunct to pharmacological therapy. The procedure’s ability to reduce airway smooth muscle mass through controlled radiofrequency energy delivery has been associated with improved quality of life scores and reduced emergency hospitalizations in long-term follow-up studies. Companies such as Boston Scientific Corporation (U.S.) are actively supporting clinical training programs and expanding procedural adoption across North America, Europe, and select Asia-Pacific markets. In addition, increasing healthcare expenditure and expansion of pulmonology departments in tertiary care hospitals are strengthening procedural accessibility. Growing physician awareness and guideline inclusion by organizations such as the Global Initiative for Asthma (GINA) are further supporting market expansion.

Key Restraint/Challenge: High Procedure Cost, Limited Access, and Requirement of Specialized Expertise

A key challenge in the Bronchial Thermoplasty Market is the high procedural cost and limited availability of specialized treatment centers. The procedure typically requires advanced bronchoscopy infrastructure, radiofrequency energy delivery systems, and highly trained interventional pulmonologists, making it concentrated in tertiary and quaternary care hospitals. In many regions, the total cost of bronchial thermoplasty can exceed USD 7,000–15,000 per patient across multiple treatment sessions, limiting accessibility in low- and middle-income countries. In addition, reimbursement coverage remains inconsistent across healthcare systems, particularly in emerging markets, which restricts widespread adoption. The need for multiple treatment sessions (typically three bronchoscopic procedures spaced weeks apart) further increases healthcare resource utilization. Concerns regarding short-term adverse effects such as transient worsening of respiratory symptoms post-procedure also contribute to cautious adoption among clinicians. Limited long-term real-world evidence in diverse populations continues to be a barrier for faster global penetration.

Key Market Opportunity: Expansion of Minimally Invasive Asthma Therapies and Integration of AI-Guided Pulmonology Care

The integration of advanced imaging, AI-assisted bronchoscopy, and digital pulmonary function monitoring presents a significant opportunity for the bronchial thermoplasty market. AI-based respiratory analytics platforms are increasingly being used to identify severe asthma phenotypes that may benefit most from interventional procedures, improving patient selection and outcomes. The growing shift toward personalized respiratory care is driving adoption of bronchial thermoplasty as part of broader biologics-plus-procedure treatment strategies, particularly in developed healthcare systems. Expanding medical tourism in countries such as India, Thailand, and Singapore—where advanced pulmonology procedures are offered at significantly lower costs—further enhances market accessibility. In addition, increasing investment in hospital infrastructure, such as the expansion of interventional pulmonology units in Europe and North America, is expected to support higher procedural volumes. The convergence of AI-driven diagnostics, improved catheter-based delivery systems, and growing clinical evidence supporting long-term asthma control positions bronchial thermoplasty as a key emerging therapeutic option in severe asthma management.

Bronchial Thermoplasty Market Scope

The Bronchial Thermoplasty market is segmented on the basis of product type and end use.

• By Product Type

On the basis of product type, the Bronchial Thermoplasty Market is segmented into Bronchial Thermoplasty Systems, Catheter-Based Ablation Devices, Radiofrequency Generators, and Accessories. The Bronchial Thermoplasty Systems segment dominated the market with a 42.18% share in 2025 due to its strong clinical preference as a complete procedural solution for severe asthma management. These systems integrate energy delivery, catheter control, and procedural monitoring into a single platform, improving treatment accuracy and procedural efficiency. Increasing adoption of minimally invasive asthma interventions across hospitals and pulmonology centers is a key factor supporting segment dominance. The availability of FDA-approved systems such as Boston Scientific’s Alair System has significantly strengthened clinical confidence and global adoption. Rising prevalence of severe persistent asthma and growing demand for non-pharmacological treatment options further support segment growth. Hospitals prefer integrated systems due to standardized treatment outcomes and reduced procedural variability. Expanding interventional pulmonology infrastructure in North America and Europe is further boosting usage. Strong reimbursement support in developed healthcare systems is enhancing accessibility. Increasing physician training programs for bronchial thermoplasty procedures is also contributing to adoption. Continuous technological upgrades in catheter compatibility and RF energy control are improving system efficiency. Overall, system-based solutions remain the backbone of the bronchial thermoplasty procedure market.

The Radiofrequency Generators segment is projected to witness the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing demand for precise and controlled energy delivery systems in airway smooth muscle ablation procedures. These generators play a critical role in ensuring consistent thermal energy application during bronchial thermoplasty, improving procedural safety and effectiveness. Advancements in RF energy modulation technology are enabling better control over tissue heating and reducing procedural complications. Rising adoption of next-generation minimally invasive respiratory therapies is significantly driving demand for advanced generators. Integration of digital feedback systems and temperature monitoring capabilities is enhancing clinical outcomes. Hospitals and specialty pulmonology centers are increasingly upgrading legacy systems to advanced RF platforms. Growing focus on personalized asthma treatment protocols is further boosting demand. Expansion of outpatient pulmonary care facilities is accelerating adoption in ambulatory settings. Increasing clinical trials evaluating improved RF-based asthma interventions are supporting market expansion. Manufacturers are focusing on compact, portable, and highly efficient generator systems. Rising healthcare investments in respiratory care infrastructure across emerging markets is further contributing to growth. Overall, technological innovation and clinical efficiency are key drivers of this segment.

• By End Use

On the basis of end use, the Bronchial Thermoplasty Market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), and Pulmonology Centers. The Hospitals segment dominated the market with a 46.73% share in 2025 due to strong infrastructure availability for complex bronchoscopic procedures and severe asthma management cases. Hospitals remain the primary treatment centers because they offer advanced interventional pulmonology units equipped with bronchoscopy suites and emergency care support. High patient inflow for chronic and severe asthma cases significantly contributes to dominance. Availability of trained pulmonologists and anesthesiology support enhances procedural safety. Hospitals also benefit from favorable reimbursement structures in developed healthcare systems. Increasing adoption of minimally invasive respiratory interventions in tertiary care hospitals is driving demand. Strong presence of multidisciplinary respiratory care teams improves treatment outcomes. Expansion of hospital networks in North America and Europe is further strengthening market share. Rising investments in advanced pulmonary diagnostic and therapeutic infrastructure are supporting procedural growth. Increasing awareness among clinicians regarding bronchial thermoplasty benefits is boosting hospital adoption. Integration of AI-based respiratory monitoring tools is enhancing procedural accuracy. Overall, hospitals remain the core execution point for bronchial thermoplasty procedures globally.

The Pulmonology Centers segment is expected to witness the fastest growth at a CAGR of 7.1% from 2026 to 2033, driven by increasing specialization in respiratory disease management and rising demand for dedicated asthma treatment facilities. These centers are emerging as key outpatient care hubs for bronchial thermoplasty due to shorter treatment cycles and reduced hospital burden. Growing preference for minimally invasive outpatient procedures is significantly supporting segment expansion. Rising prevalence of severe asthma cases globally is increasing patient visits to specialized respiratory clinics. Development of dedicated asthma and allergy care centers in urban healthcare systems is accelerating adoption. Increasing physician preference for focused pulmonology practices is enhancing procedural efficiency. Lower treatment costs compared to hospitals are attracting patients to specialty centers. Expansion of healthcare infrastructure in emerging economies is further boosting availability of pulmonology centers. Integration of advanced diagnostic tools and portable RF systems is improving accessibility. Rising awareness of early asthma intervention is increasing outpatient procedure rates. Telemedicine-supported follow-up care is further strengthening this segment. Overall, pulmonology centers are emerging as high-growth outpatient hubs for bronchial thermoplasty procedures.

Bronchial Thermoplasty Market Regional Analysis

North America dominated the Bronchial Thermoplasty Market with the largest revenue share of 38.91% in 2025, supported by high prevalence of severe asthma cases, advanced healthcare infrastructure, and strong adoption of interventional pulmonology procedures across hospitals and specialty respiratory care centers. The region benefits from well-established respiratory care networks, strong reimbursement frameworks, and early adoption of minimally invasive bronchial thermoplasty procedures for severe persistent asthma management. The United States is the key contributor in the region, driven by high healthcare expenditure, strong presence of leading medical device companies such as Boston Scientific Corporation, and widespread availability of FDA-approved bronchial thermoplasty systems. Canada also contributes significantly due to growing awareness of severe asthma treatment options and expanding access to specialized pulmonology care centers. Increasing use of AI-assisted respiratory diagnostics and digital pulmonary monitoring tools is further enhancing treatment outcomes. Rising hospital investments in advanced bronchoscopy suites and interventional pulmonology infrastructure are strengthening procedural adoption. Growing focus on reducing asthma-related hospitalizations and emergency visits is further driving demand. Continuous clinical evidence supporting long-term efficacy of bronchial thermoplasty is reinforcing physician confidence. Expansion of specialty respiratory clinics and asthma management programs is also supporting market growth. Increasing adoption of outpatient-based minimally invasive procedures is improving accessibility. Overall, North America remains the leading region due to strong clinical adoption and advanced healthcare systems.

U.S. Bronchial Thermoplasty Market Insight

The U.S. Bronchial Thermoplasty market is witnessing strong growth due to rising prevalence of severe asthma, increasing adoption of advanced interventional pulmonology procedures, and strong healthcare infrastructure. The country has a high burden of asthma patients, with millions affected by uncontrolled or severe persistent asthma requiring advanced treatment options. Hospitals and specialty respiratory centers are increasingly adopting bronchial thermoplasty as a complementary treatment to pharmacological therapy. Strong presence of medical device companies such as Boston Scientific Corporation supports technological innovation and procedural availability. Increasing use of AI-based respiratory monitoring and digital health platforms is improving patient selection and treatment outcomes. Growing reimbursement support for interventional asthma procedures is encouraging wider adoption. Rising investments in hospital bronchoscopy units and outpatient pulmonology clinics are further boosting market penetration. Clinical guidelines supporting bronchial thermoplasty for severe asthma management are strengthening physician acceptance. Expansion of ambulatory care settings is improving procedural accessibility. Increasing focus on reducing asthma-related emergency admissions is also driving demand. Continuous clinical trials and real-world evidence generation are enhancing confidence in long-term efficacy. Overall, the U.S. remains the largest contributor within North America.

Europe Bronchial Thermoplasty Market Insight

The Europe Bronchial Thermoplasty market remains a major contributor to global revenue, driven by strong healthcare systems, increasing prevalence of severe asthma, and growing adoption of minimally invasive respiratory interventions. The region benefits from advanced pulmonology infrastructure, well-trained healthcare professionals, and supportive clinical guidelines for asthma management. Countries such as Germany, France, and the U.K. are key contributors due to strong hospital networks and early adoption of interventional respiratory procedures. Increasing investment in specialty respiratory care centers is enhancing procedural access. Rising awareness of severe asthma treatment options is driving patient demand for bronchial thermoplasty. Growing adoption of digital respiratory monitoring and AI-based diagnostic tools is improving clinical decision-making. Expansion of outpatient pulmonary care facilities is supporting procedural growth. Strong government healthcare policies and reimbursement frameworks in several European countries are encouraging adoption. Increasing focus on reducing long-term corticosteroid dependency is also supporting demand. Continuous medical training programs in interventional pulmonology are enhancing physician capability. Overall, Europe continues to maintain strong market presence through innovation and structured healthcare systems.

U.K. Bronchial Thermoplasty Market Insight

The U.K. Bronchial Thermoplasty market is experiencing steady growth, supported by increasing prevalence of severe asthma, strong NHS healthcare infrastructure, and rising adoption of advanced respiratory interventions. Hospitals and specialized respiratory clinics are increasingly offering bronchial thermoplasty as part of severe asthma management pathways. Growing focus on reducing hospital admissions and improving long-term asthma control is driving procedural adoption. Increasing availability of trained interventional pulmonologists is supporting market expansion. Integration of digital respiratory monitoring tools is enhancing treatment precision. Strong clinical guidelines supporting bronchial thermoplasty adoption are improving physician confidence. Expansion of specialty asthma centers is increasing accessibility. Rising investments in hospital bronchoscopy infrastructure are further supporting growth. Increasing use of minimally invasive procedures in outpatient settings is improving patient convenience. Growing awareness campaigns about severe asthma management are boosting patient uptake. Overall, the U.K. remains a key innovation-driven market in Europe.

Germany Bronchial Thermoplasty Market Insight

The Germany Bronchial Thermoplasty market is expanding steadily due to strong healthcare infrastructure, high prevalence of respiratory diseases, and advanced clinical research capabilities. Hospitals and specialty pulmonology centers are increasingly adopting bronchial thermoplasty for severe asthma treatment. Strong emphasis on medical innovation and interventional pulmonology is driving adoption. Increasing availability of advanced bronchoscopy systems is supporting procedural growth. Rising clinical research activities in respiratory medicine are strengthening evidence-based adoption. Integration of digital health tools and AI-assisted diagnostics is improving treatment outcomes. Strong hospital networks and skilled pulmonologists are enhancing procedural access. Growing awareness of non-pharmacological asthma treatment options is boosting demand. Expansion of outpatient respiratory care services is improving accessibility. Government focus on improving chronic disease management is supporting market growth. Overall, Germany remains a key European contributor due to strong innovation and healthcare systems.

Asia-Pacific Bronchial Thermoplasty Market Insight

The Asia-Pacific Bronchial Thermoplasty market is expected to witness rapid growth, driven by rising asthma prevalence, improving healthcare infrastructure, and increasing awareness of advanced respiratory treatments. Countries such as China, India, and Japan are key growth contributors due to expanding hospital networks and rising patient population. Increasing investment in pulmonology departments is improving access to advanced procedures. Growing adoption of minimally invasive therapies is supporting market expansion. Rising healthcare expenditure and improving insurance coverage are enhancing affordability. Increasing training of interventional pulmonologists is strengthening procedural availability. Expansion of specialty respiratory clinics is supporting outpatient adoption. Growing awareness of severe asthma management is increasing patient demand. Adoption of digital health and diagnostic tools is improving clinical efficiency. Increasing collaborations with global medical device companies are boosting technology penetration. Overall, Asia-Pacific is emerging as the fastest-growing regional market.

Japan Bronchial Thermoplasty Market Insight

The Japan Bronchial Thermoplasty market is witnessing consistent growth due to advanced healthcare infrastructure, rising asthma burden, and strong focus on respiratory disease management. Hospitals and specialty clinics are increasingly adopting bronchial thermoplasty for severe asthma cases. Strong emphasis on minimally invasive procedures is driving adoption. Increasing integration of AI-based diagnostics is improving treatment accuracy. Growing geriatric population is contributing to higher asthma-related complications. Expansion of pulmonology departments is supporting procedural availability. Strong clinical research environment is promoting innovation in respiratory care. Rising awareness of advanced asthma therapies is boosting patient demand. Increasing use of outpatient treatment models is improving accessibility. Government support for chronic disease management is strengthening healthcare delivery. Overall, Japan remains a technologically advanced and stable market.

China Bronchial Thermoplasty Market Insight

The China Bronchial Thermoplasty market is growing rapidly, driven by increasing asthma prevalence, expanding healthcare infrastructure, and rising adoption of advanced respiratory therapies. Hospitals and specialty pulmonary centers are increasingly adopting bronchial thermoplasty procedures. Growing investments in tertiary care hospitals are improving access to advanced treatment options. Rising awareness of severe asthma management is increasing patient demand. Expansion of pulmonology departments in urban hospitals is supporting procedural growth. Increasing adoption of minimally invasive procedures is improving patient outcomes. Strong government healthcare reforms are supporting chronic disease management. Growing medical tourism and private healthcare expansion are boosting advanced treatment availability. Increasing collaboration with global medical device companies is enhancing technology adoption. Rising clinical training programs for pulmonologists are improving procedural expertise. Overall, China is emerging as one of the fastest-growing markets globally.

Bronchial Thermoplasty Market Share

The Bronchial Thermoplasty industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• Olympus Corporation (Japan)
• Teleflex Incorporated (U.S.)
• Medtronic plc (Ireland)
• Koninklijke Philips N.V. (Netherlands)
• Johnson & Johnson (U.S.)
• Cook Medical (U.S.)
• CONMED Corporation (U.S.)
• Merit Medical Systems Inc. (U.S.)
• APT Medical Inc. (China)
• MicroPort Scientific Corporation (China)
• FUJIFILM Holdings Corporation (Japan)
• Karl Storz SE & Co. KG (Germany)
• Becton, Dickinson and Company (U.S.)
• Stryker Corporation (U.S.)
• Smith & Nephew plc (U.K.)
• Abbott Laboratories (U.S.)
• Pentax Medical (Japan)
• Biotronik SE & Co. KG (Germany)
• Penlon Limited (U.K.)
• Schiller AG (Switzerland)
• Intuitive Surgical, Inc. (U.S.)
• Hoya Corporation (Japan)
• Laborie Medical Technologies (Canada)
• Ambu A/S (Denmark)
• Richard Wolf GmbH (Germany)
• Hill-Rom Holdings (U.S.)
• GE HealthCare (U.S.)
• Siemens Healthineers (Germany)
• Drägerwerk AG (Germany)
• Mindray Medical International (China)
• Terumo Corporation (Japan)
• Edwards Lifesciences (U.S.)
• Nihon Kohden Corporation (Japan)
• Cardinal Health (U.S.)
• Vyaire Medical (U.S.)
• Nipro Corporation (Japan)

Latest Developments in Bronchial Thermoplasty Market

• In February 2021, results from the TASMA randomized clinical trial evaluating bronchial thermoplasty in severe asthma patients were published, demonstrating that airway smooth muscle reduction through bronchial thermoplasty leads to measurable clinical improvement in asthma control and symptom reduction. The study reinforced the long-term mechanistic effectiveness of bronchial thermoplasty in reducing airway hyperresponsiveness and supporting its role in severe asthma management
• In May 2021, long-term follow-up results published in Lancet Respiratory Medicine showed that bronchial thermoplasty provides sustained clinical benefits for up to 10 years in patients with severe asthma, including reduced exacerbation rates and improved quality of life. These findings strengthened clinical confidence in the durability of bronchial thermoplasty outcomes beyond the initial treatment period
• In March 2022, results from the PAS2 post-FDA approval clinical trial (5-year evaluation) were reported in Chest Journal, confirming that bronchial thermoplasty delivers sustained reductions in severe asthma exacerbations, emergency visits, and hospitalizations in real-world clinical settings. The study validated long-term safety and effectiveness in routine medical practice
• In October 2022, extended real-world evidence from long-term follow-up of bronchial thermoplasty patients was published, demonstrating continued reductions in oral corticosteroid dependency and improved asthma-related quality-of-life scores over a multi-year period. These findings supported wider adoption in interventional pulmonology centers for severe uncontrolled asthma cases
• In October 2023, Boston Scientific continued global expansion of the Alair Bronchial Thermoplasty System, reinforcing commercialization in international markets following earlier FDA (2010) and China regulatory approvals (2013). The system remained the only FDA-approved device for bronchial thermoplasty and was increasingly integrated into specialized respiratory care programs globally for severe asthma treatment
• In November 2025, updated clinical policy guidance and real-world evidence summaries highlighted bronchial thermoplasty as a treatment option for carefully selected patients with severe asthma not controlled by pharmacological therapy. However, guidelines emphasized that due to limited long-term comparative evidence, bronchial thermoplasty should be performed under specialist care with registry-based monitoring

SKU-76017